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Abstract
Background: Throughout most of sub-Saharan Africa (and, indeed, most resource-limited areas), lack of death
registries prohibits linkage of cancer diagnoses and precludes the most expeditious approach to determining
cancer survival. Instead, estimation of cancer survival often uses clinical records, which have some mortality data
but are replete with patients who are lost to follow-up (LTFU), some of which may be caused by undocumented
death. The end result is that accurate estimation of cancer survival is rarely performed. A prominent example of a
common cancer in Africa for which survival data are needed but for which frequent LTFU has precluded accurate
estimation is Kaposi sarcoma (KS).
Methods: Using electronic records, we identified all newly diagnosed KS among HIV-infected adults at 33 primary
care clinics in Kenya, Uganda, Nigeria, and Malawi from 2009 to 2012. We determined those patients who were
apparently LTFU, defined as absent from clinic for ≥90 days at database closure and unknown to be dead or transferred.
Using standardized protocols which included manual chart review, telephone calls, and physical tracking in the community,
we attempted to update vital status amongst patients who were LTFU.
Results:We identified 1222 patients with KS, of whom 440 were LTFU according to electronic records. Manual chart review
revealed that 18 (4.1%) were classified as LFTU due to clerical error, leaving 422 as truly LTFU. Of these 422, we updated vital
status in 78%; manual chart review was responsible for updating in 5.7%, telephone calls in 26%, and physical tracking in
46%. Among 378 patients who consented at clinic enrollment to be tracked if they became LTFU and who had sufficient
geographic contact/locator information, we updated vital status in 88%. Duration of LTFU was not associated with success
of tracking, but tracking success was better in Kenya than the other sites.
Conclusion: It is feasible to update vital status in a large fraction of patients with HIV-associated KS in sub-Saharan Africa
who have become LTFU from clinical care. This finding likely applies to other cancers as well. Updating vital status amongst
lost patients paves the way towards accurate determination of cancer survival.
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Background
Knowledge of survival after a cancer diagnosis is one of
the fundamental metrics in cancer epidemiology. Accur-
ate survival estimation requires a representative sample
(if not census) of patients diagnosed with a particular
malignancy as well as knowledge of vital status in all
patients following diagnosis. In resource-rich settings,
accurate estimation of cancer survival is achieved by
combining data from well-curated cancer registries (to
identify the cases) and death registries (to ascertain vital
status) [1]. In resource-poor settings, however, estima-
tion of cancer survival is elusive. For example, in sub-
Saharan Africa, only four cancer registries are deemed to
be high quality by the International Agency for Research
on Cancer (IARC) [2] and death registries are limited to
one country [3]. Without registries, most attempts at
cancer survival estimation in sub-Saharan Africa come
from facility-based samples (i.e., clinical care), which not
only suffer from uncertain representativeness but also
have high rates of patients ceasing to return to care
without knowledge of their vital status (a phenomenon
termed “lost to follow-up” — LTFU). For example, a
recent Ethiopian study of survival of cervical cancer had
almost 35% LTFU at 2 years [4]. Because it is unwise to
assume that patients with cancer who cease to return to
care experience similar survival as those whose vital
status is documented, accurate survival estimation in the
face of sizeable LTFU is precluded.
One cancer in sub-Saharan Africa that needs a better
understanding of its survival is Kaposi sarcoma (KS).
Even before the HIV epidemic, KS was among the more
common cancers in Africa [5, 6], and it exploded in inci-
dence after HIV appeared [7–9]. During the early HIV
epidemic, when there was no therapy, KS was associated
with very poor survival [8, 10]; this was apparent even
with high LTFU. The advent of antiretroviral therapy
(ART) has substantially improved KS survival in
resource-replete settings [11–13], and ART is now fortu-
nately more widely available in resource-poor regions
[14]. Improved survival in the ART era in resource-rich
settings, however, cannot blithely be extrapolated to
resource-poor settings. Rather, we must study KS
survival directly in Africa if we hope to understand the
impact of ART in this region. Unfortunately, accurate
estimation of contemporary KS survival in Africa has
typically been stymied by high LTFU [15–18].
In an attempt to overcome the problem that LTFU
presents for cancer survival estimation in Africa, we de-
veloped a process whereby we sought after patients who
had become LTFU in order to update their vital status.
Tracking lost cancer patients has been rarely performed
in sub-Saharan Africa [19–21] and little has been
described regarding its success. We sought after a large
group of lost patients with HIV-related KS in whom our
objective was to determine the overall success in updat-
ing vital status, assess the relative contribution of differ-
ent aspects of the search process; and evaluate key
determinants of tracking success.
Methods
Overall design
At HIV primary care clinics in 4 countries in sub-
Saharan Africa, we identified all patients newly diag-
nosed with KS via a search of electronic databases.
Among these patients with KS, we then used the data-
base to determine who appeared to be LTFU. Among
those who appeared to be LTFU, we attempted to update
their vital status using manual chart review, telephone
calls, and physical tracking in the community.
Study population
Through a search of the electronic databases that hold
clinical records at each site, we identified all HIV-
infected adults (≥18 years old) newly diagnosed with KS
from January 2009 to December 2012 while receiving
primary care at one of 33 ambulatory clinics in Kenya,
Uganda, Malawi, and Nigeria. The sites included 26
clinics in a network in western Kenya (Academic Model
Providing Access to Healthcare (AMPATH) [22]), one
clinic in Uganda (Immune Suppression Syndrome (ISS)
Clinic in Mbarara), one clinic from Malawi (Lighthouse
Trust in Lilongwe) [23], and two clinics in Nigeria (Uni-
versity of Abuja Teaching Hospital (UATH) and National
Hospital of Abuja (NHA)). All these sites participate in
the International Epidemiologic Databases to Evaluate
AIDS (IeDEA) Consortium. Established in 2005 by the
U.S. National Institutes of Health, the IeDEA Consor-
tium has as its main objective the harmonization of data
collected by geographically disparate, but representative,
cohorts of persons infected with HIV [24, 25]. Each of
these clinics is prototypical for HIV primary care in its
respective region and administers free ART following
national guidelines. At all these clinics, it was routine
practice to attempt to obtain patients’ telephone
contacts and location of their residences at the time of
initial enrollment into care. All sites also had routine
procedures available to attempt to contact, by telephone
or by physical tracking, patients who had failed to return
for clinic visits shortly after they became lost, but scarce
resources often prohibited these from occurring.
Among the patients with newly diagnosed KS, we then
used the respective databases to identify those who were
apparently LTFU, as defined by being absent from clinic
for at least 90 days at the time of database closure, not
known to be dead, and not known to have transferred to
another facility (D1 in Fig. 1). For each patient believed
to be LTFU, we manually reviewed the paper-based
clinic chart for evidence of visits, deaths, or transfers
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after the last recorded date of being seen that did not
get captured in the electronic database. Those who were
still LTFU at the time of database closure after this
manual inspection were considered truly LTFU (N1a + D2
in Fig. 1).
Approval for this research was granted by each site’s
institutional review board.
Measurements
KS
Diagnosis of KS was made during the course of routine
clinical care, either by physical examination alone or
with histologic confirmation. Both patients who were
diagnosed at their first clinic visit and during subsequent
care were included.
Updating vital status among the LTFU
Among those truly LTFU, we attempted to update vital
status, beginning with manual chart review, telephone
calls, and finally physical tracking in the community. As
noted above, manual chart review had been performed
on all apparently lost patients to identify any evidence
up to the time of database closure that inadvertently did
not get captured in the electronic database. Yet, even if
the electronic database had captured all events that had
occurred, because there was a delay between database
closure and time the search began for a patient believed
to be LTFU, manual chart review was also deemed useful
because it would detect events (return to care, death, or
recorded transfers) that occurred after the time of data-
base closure. Therefore, charts were thoroughly reviewed
for their most recent entries that gave any evidence that
the patient was either alive or dead. In addition, for
those without recent entries, we searched for new phone
numbers or geographic locator information that was not
present in the electronic database. For telephone track-
ing, only patients who had provided consent to be called
(or to have relatives/friends called) when they enrolled
Insufficient locator information: No 
physical tracking attempted (IL)
n=34
Found patient or 
informant (N3)
n=196
Presumed LTFU in EMR (D1)
n=440
Did not find patient 
or informant 
n=47
Found patient or 
informant (N2)
n=111
Not found by 
phone tracking
Did not consent to 
physical tracking (NC)
n=10
Vital status (in relation to 
database closure date) found 
from chart/records review (N1)
n=42
Vital status at database 
closure still missing after 
manual review (D2)
n=398
Not LTFU: Vital status 
known at time of 
database closure
n=782
All eligible patients 
with Kaposi’s sarcoma
N=1,222
Vital status update is after database 
closure; therefore, information would not 
be captured in database at time of 
database closure (N1a)
n=24
Vital status update is prior to 
database closure; therefore, 
information should have been in the 
database at database closure (N1b)
n=18
Assess electronic 
medical records (EMR) 
through date of 
database closure
Manual review of chart 
and other readily 
ambient records
Assessed phone 
number availability & 
consent 
Phone number available 
& consent given to use it 
for tracking
Phone number not 
available or consent not 
given to use it
Sufficient locator information: 
Physical tracking attempted (D3)
n=243
Fig. 1 Flow diagram summarizing the logic of the tracking process. Ovals refer to procedures and rectangles refer to outcomes of procedures.
Abbreviations (e.g., N1) refer to numeric metrics of the process that are referred to in the text. Numbers shown are for the entire population
across all four sites. LTFU denotes lost to follow-up
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in clinic were contacted. This consent was requested as
part of routine clinical care at the sites and not for the
purposes of or in anticipation of a research study.
Telephone tracking involved using all available phone
numbers to call the patient. Calls were attempted at least
three times a day on three different days of the week over
a period of three weeks until contact was made with either
the patient or an informant close to the patient.
Physical tracking was performed for those patients not
found by phone, who had consented to be tracked if they
had become lost, and who had sufficient geographic
locator information (D3 in Fig. 1) to begin a physical
search. Again, the documentation of geographic infor-
mation was done during routine clinical care and did
not have any special emphasis in anticipation of
research. If there was sufficient locator detail to pursue
physical tracking, the tracking was performed by a
trained research associate (a “tracker”) for whom the
minimal requirements were an intimate understanding
of the local dialect, customs, geography and social rela-
tionships. Trackers were typically identified amongst
existing staff whose current responsibility was, at least in
part, to search for lost patients for clinical purposes,
namely to bring them back into care. No explicit health
care background or education was required; most
trackers were some form of community health workers.
Prior to commencing the tracking process, the trackers
at each site underwent an in-person training conducted
by one of the central investigators (A.S. or E.F.) to en-
sure that standard procedures were followed across sites.
Training emphasized maintenance of privacy, avoidance
of HIV status disclosure and attentiveness to sensitivity
when interacting with HIV-infected patients or their
close relatives. For example, trackers used unmarked
cars or public transport during the tracking. Importantly,
as opposed to the tracking that had previously been
done at some of the sites where the goal was to look for
as many lost patients as possible and encourage those
who were lost to return, the emphasis for the present
study was to look for a limited number of lost patients
and spend a considerable amount of time, if needed, to
find each [26]. Specifically, if the initial attempt was un-
successful, trackers made at least one additional attempt
and, in many instances, made two additional attempts.
Tracking was overseen by a local supervisor, but all
patients who were difficult to find were discussed with
one of the central investigators (either A.S. or E.F.) and
consensus was reached prior to deciding to stop tracking
a particular patient. Trackers were charged with finding
the lost patient, or failing that, a close informant who
knew the patient’s vital status. If the tracker found the
patient, the date of the encounter was documented. If
only an informant who knew the lost patient, was identi-
fied, the tracker recorded either the date of death or the
most recent date the informant knew the patient was
alive. A single informant’s report of death was consid-
ered final; there was no attempt to confirm this was
another informant, and there were no municipal death
registries to cross reference. Searching for multiple
patients simultaneously in the same geographic area was
encouraged for cost saving.
Other measurements
We used the electronic database to obtain age, sex, date
of KS diagnosis, date of ART start (if applicable), and
date of last clinic visit. We subsequently derived
duration since KS diagnosis (time from KS diagnosis to
date last seen at clinic) and duration of LTFU (time from
last visit to database closure).
Statistical analysis
For those patients with KS who were LTFU, we first
described the success of updating vital status using the
three approaches: manual chart review, telephone calls,
and physical tracking. Among those patients who were
truly LTFU with no recent record of a visit to the clinic
upon manual chart review, had sufficient locator infor-
mation to perform a search, and had provided consent
to search for them, we then assessed the independent
influence of two factors (duration of being lost and geo-
graphic clinic site) on successful tracking. The rationale
for examining duration of being lost was to inform pro-
grams when, if ever, it becomes too late to search for a
lost patient. The rationale for evaluating geographic site
was to determine if some aspect of the socio-geographic
environment influences success of tracking. The out-
come in this analysis was failure to update vital status
after telephone and field tracking. The relationships
between duration of being lost, geographic site, and fail-
ure to locate a lost patient were depicted with risk ratios,
which were derived from log binomial regression. In
these models, we adjusted for age, sex, duration with KS,
and ART status. Multiplicative interaction between dur-
ation being lost and geographic site was also evaluated.
All analyses were performed using Stata (version 13.1,
Stata Corp., College Station, Texas).
Results
Identification and characteristics of the population of
patients who were LTFU
In total, 1222 patients were diagnosed with KS (32% with
biopsy confirmation) during the study period: 678 in Kenya,
173 in Uganda, 314 in Malawi, and 57 in Nigeria. Of these,
440 (D1 in Fig. 1) appeared to be LTFU according to the
electronic databases. Manual review of the paper clinic
charts, however, revealed that 18 (4.1%) should not have
been counted as LTFU (N1b in Fig. 1) but were erroneously
missed in the electronic database (Table 1). Therefore, 422
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were truly LTFU (N1a + D2 in Fig. 1), and in this
population, 65% were men, the median age was
35 years, 73% had started ART, the median CD4+ T
cell count was 159 cells/mm3, the median duration
from KS diagnosis to last visit was 1.4 months, and
the median duration between last visit and database
closure was 21 months (Table 2).
Feasibility of searching for patients truly LTFU
Among the 422 patients who were truly LTFU (N1a + D2
in Fig. 1), we updated vital status among 331 (78%)
(Table 1). Manual chart review was responsible for up-
dating vital status in 24 patients (5.7%), as these patients
(N1a in Fig. 1), who had been LTFU as of the date of
database closure, re-appeared at clinic shortly after
Table 1 Disposition and success of updating vital status through manual record review, phone tracking, and physical tracking
amongst patients newly diagnosed with Kaposi sarcoma in four countries in sub-Saharan Africa
AMPATH
- Kenya
ISS
- Uganda
Lighthouse-
Malawi
UATH & NHA -
Nigeria
Overall
Patients diagnosed with Kaposi sarcoma 678 173 314 57 1222
Presumed LTFU in EMR (D1 in Fig. 1) 249 80 75 36 440
Reclassification after manual review of LTFU in EMR
Not truly LTFU: Vital status determined via manual
review (N1b in Fig. 1)
16 1 1 0 18
Truly LTFU but vital status determined by repeat later
review of records (N1a in Fig. 1)
11 0 2 11 24
Truly LTFU: Vital status missing after review of all records
(D2 in Fig. 1)
222 79 72 25 398
Disposition of those who appear LTFU in EMR (D1 in Fig. 1)
Vital status updated by manual records review 27/249 (11%) 1/80 (1.3%) 3/75 (4.0%) 11/36 (31%) 42/440 (9.6%)
Vital status updated by phone contact alone 83/249 (33%) 10/80 (13%) 3/75 (4.0%) 15/36 (42%) 111/440 (25%)
Vital status updated by physical tracking 124/249 (50%) 47/80 (59%) 22/75 (29%) 3/36 (8.3%) 196/440 (45%)
Vital status not updated: consent available 15/249 (6.0%) 22/80 (28%) 37/75 (49%) 7/36 (19%) 81/440 (18%)
Vital status not updated: consent not available 0/249 (0%) 0/80 (0%) 10/75 (13%) 0/36 (0%) 10/440 (2.3%)
Disposition of those who were truly LTFU (N1a + D2 in Fig. 1)
Vital status updated by manual records review 11/233 (4.7%) 0/79 (0%) 2/74 (2.7%) 11/36 (31%) 24/422 (5.7%)
Vital status updated by phone contact alone 83/233 (36%) 10/79 (13%) 3/74 (4.1%) 15/36 (42%) 111/422 (26%)
Vital status updated by physical tracking 124/233 (53%) 47/79 (59%) 22/74 (30%) 3/36 (8.3%) 196/422 (46%)
Vital status not updated: consent available 15/233 (6.4%) 22/79 (28%) 37/74 (50%) 7/36 (19%) 81/422 (19%)
Vital status not updated: consent not available 0/233 (0%) 0/79 (0%) 10/74 (14%) 0/36 (0%) 10/422 (2.4%)
Disposition of those truly LTFU not found by manual records review (D2 in Fig. 1)
Vital status updated by phone contact alone 83/222 (37%) 10/79 (13%) 3/72 (4.2%) 15/25 (60%) 111/398 (28%)
Vital status updated by physical tracking 124/222 (56%) 47/79 (59%) 22/72 (31%) 3/25 (12%) 196/398 (49%)
Vital status not updated: consent available 15/222 (6.8%) 22/79 (28%) 37/72 (51%) 7/25 (28%) 81/398 (20%)
Vital status not updated: consent not available 0/222 (0%) 0/79 (0%) 10/72 (14%) 0/25 (0%) 10/398 (2.5%)
Disposition of those truly LTFU who were physically sought after in the community (D3 in Fig. 1)
Vital status updated by physical tracking 124/131 (95%) 47/69 (68%) 22/35 (63%) 3/8 (38%) 196/243 (81%)
Vital status not updated 7/131 (5.3%) 22/69 (32%) 13/35 (37%) 5/8 (63%) 47/243 (19%)
Success of tracking using combination of methods among those who consented and had sufficient information for tracking
Records, phone contact & physical trackinga 218/225 (97%) 57/79 (72%) 27/40 (68%) 29/34 (85%) 331/378 (88%)
Phone contact & physical trackingb 207/214 (97%) 57/79 (72%) 25/38 (66%) 18/23 (78%) 307/354 (87%)
LTFU denotes lost to follow-up; EMR denotes electronic medical records; AMPATH denotes Academic Model Providing Access to Healthcare; ISS denotes Immune
Suppression Syndrome; UATH denotes University of Abuja Teaching Hospital and NHA denotes National Hospital of Abuja
a Success of tracking using all information available from the manual records review, telephone, and field tracking amongst those truly LTFU and who gave
consent to be sought after. This is (N1a + N2 + N3) / (D1-N1b-NC-IL) in Fig. 1
b Success of tracking using information available from telephone and physical tracking amongst those truly LTFU, not updated by manual review, and who gave
consent to be sought after. This is (N2 + N3) / (D2-NC-IL) in Fig. 1
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database closure. This occurred at 3 of the 4
participating sites, and at one site (Nigeria) represented
a substantial fraction (31%) of the truly LTFU popula-
tion. Telephone calls were responsible for updating vital
status in 111 patients (26%), and physical tracking in the
community identified the largest fraction of updated
vital status — 196 patients (46%). There were some not-
able differences between sites in terms of which means
of investigation were more useful in updating vital sta-
tus. For example, in Nigeria, 73% of patients had their
vital status updated simply by manual chart review and
telephone calls, obviating the need for more expensive
physical tracking in the community. In contrast, in
Malawi and Uganda, only 7% and 13% of patients, re-
spectively, had their vital status updated by the two inex-
pensive methods. After eliminating the 24 patients who
had re-appeared in clinic after database closure, there
remained 398 patients in the truly LTFU population (D2
in Fig. 1), and, of these, 307 (77%) had their vital status
eventually updated (Table 1). Similar to the entire truly
LTFU population, 111 of the 398 (28%) had their vital
status updated by telephone calls, and 196 (49%) were
updated by physical tracking in the community.
Because the search for lost patients in this study was
done in clinics that were not prospectively selected,
there had been no dedicated emphasis on obtaining con-
sent from patients to be sought if they became lost or
on optimizing the telephone contacts or geographic de-
tail in the locator information regarding the patient’s
community residence. This was apparent in that of the
422 patients who were truly lost, 44 (10%) either did not
provide consent (NC in Fig. 1) or did not have sufficient
residence locator information for a physical search to be
initiated (IL in Fig. 1). Thus, when assessing the entire
available LTFU population, we cannot observe just how
successful our tracking procedures might have been if
we had been working with clinics that had been primed
for this activity. To attempt to address this, we next lim-
ited the truly LTFU population to the 378 who had pro-
vided consent to be sought after and had sufficient
geographic locator information for a search to be
attempted (i.e., those having potential to be found). In
this group, we were able to update vital status in 331
(88%) across all sites, which varied from 68% to 97%
between sites (Table 1). In this group of truly LTFU for
whom there was some potential of being found, after
eliminating those patients whose status was updated
through manual chart review, there were 354 patients
remaining. Of these 354, we were able to update vital
status in 307 (87%) via either telephone contact or
physical tracking.
Determinants of successful tracking by telephone and
physical tracking
To evaluate the influence of duration of being lost and
geographic clinic site on the ability to successfully update
the vital status of lost patients by either telephone or phys-
ical tracking, we again restricted the population of truly
Table 2 Characteristics of patients with Kaposi sarcoma who were lost to follow-up in four countries in sub-Saharan Africa
(N1a + D2 in Fig. 1)
AMPATH
- Kenya
N = 233
ISS
- Uganda
N = 79
Lighthouse
- Malawi
N = 74
UATH & NHA
- Nigeria
N = 36
Overall
N = 422
Age at last visit, yearsa 35 (30–42)b 32 (29–40) 34 (29–40) 36 (32–42) 35 (29–41)
Male sexa 62% 68% 78% 51% 65%
ART in use at last visit 82% 77% 47% 58% 73%
CD4+ T-cells/mm3 at last visitc 126 (39–287) 183 (110–317) 231 (141–387) 259 (177–308) 159 (60–312)
CD4+ T-cells/mm3 at last visitc, category
0–50 28% 17% 6.7% 7.7% 22%
51–100 15% 4.4% 6.7% 7.7% 12%
101–200 23% 30% 27% 23% 24%
201–350 18% 30% 33% 46% 24%
351–500 9.4% 13% 20% 0% 10%
> 500 7.3% 4.4% 6.7% 15% 7.5%
Duration since KS diagnosis at last visit, months 0.96 (0–3.5) 1.9 (0.3–4.7) 1.9 (0–8.3) 4.7 (0.6–18.1) 1.4 (0.03–5.1)
Duration of being lost at database closure, months 17 (11–22) 30 (19–39) 31 (17–47) 26 (14–46) 21 (13–30)
ART denotes antiretroviral therapy; AMPATH denotes Academic Model Providing Access to Healthcare; ISS denotes Immune Suppression Syndrome; UATH denotes
University of Abuja Teaching Hospital; and NHA denotes National Hospital of Abuja
a Age missing for 1 person in AMPATH and 1 person in UATH/NHA; sex is missing for 1 person in UATH/NHA
b median (Interquartile range) unless otherwise noted
c 65% missing CD4 count overall (59% AMPATH, 71% ISS, 80% Lighthouse, and 64% UATH/NHA)
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LTFU to the 354 who had provided consent to be
searched for, had sufficient geographic locator information
for which to base a search, and whose vital status was not
updated through manual chart review. In the unadjusted
analysis, both duration lost and geographic site were asso-
ciated with successful tracking (Table 3). After adjustment
for age, sex, duration since KS diagnosis, and ART status,
duration lost was no longer significant (Table 3 and
Fig. 2). There is thus no strong evidence that there is a
duration of time that a patient is lost (at least up to the
5 years we evaluated) after which searching should not be
attempted. Geographic site, however, remained significant.
Compared to AMPATH-Kenya, patients traced at the
other three sites were between 8.7 and 12.1 times more
likely not to be found (p < 0.001). We did not find strong
evidence of statistical interaction between geographic
location and duration of being lost.
Discussion
In contrast to resource-rich settings, estimates of cancer
survival in sub-Saharan Africa are rare and, even when
available, typically have substantial threats to validity.
With the ultimate goal of improving the accuracy of the
estimation of cancer survival in sub-Saharan Africa, we
evaluated the feasibility of searching for a primary care-
based sample of patients with HIV-associated KS who
had become LTFU from clinical care in 4 different
countries. A combination of manual record review, tele-
phone calls, and physical tracking in the community re-
sulted in updating the vital status of a substantial
fraction of these lost patients. While duration of being
lost did not influence ability to find lost patients, the
level of tracking success did vary by geographic site.
Although prior work has recognized the need to
search for lost patients in order to accurately estimate
cancer survival in sub-Saharan Africa, there is a paucity
of data evaluating the feasibility of the tracking process.
In the most ambitious prior attempts to estimate cancer
survival, performed in Uganda (N = 2337 covering 14
different cancers) and Zimbabwe (N = 2090 across 15
different cancers), at least 27% (and as many as 49%) of
patients in Uganda and 6.6% in Zimbabwe were LTFU
[19, 20]. Both studies attempted physical tracking to up-
date vital status but unfortunately did not describe the
success of these efforts. Of note, this work was done in
the context of cancer registries, which although nomin-
ally population-based have had their representativeness
critiqued [27, 28]. More recently, Maskew et al., using a
primary care-based sample (similar to ours) in South
Africa of 247 patients with HIV-related KS who were
initiating therapy, observed a rate of LTFU of 13 per
100 person-years. The authors employed “active
tracing” of lost patients, but the mechanistic details
or success were not reported [29]. Finally, Galukande
Table 3 Determinants of failure to find patients with Kaposi sarcoma who were lost to follow-up in four countries in sub-Saharan
Africa. Sample is limited to patients who gave consent for tracking and who had sufficient information to attempt physical tracking
(n = 354)
Unadjusted Adjusteda
Risk Ratio
(95% CI)
P value Risk Ratio
(95% CI)
P value
Age at last visit, per 1 year increase 0.98 (0.95–1.01) 0.21 1.0 (0.97–1.03) 0.87
Sex
Women Ref. Ref.
Men 0.72 (0.42–1.23) 0.23 0. 59 (0.35–1.01) 0.055
Duration of being lost at database closure, per 1 month increase 1.03 (1.02–1.05) <0.001 0.99 (0.98–1.01) 0.48
Duration since KS diagnosis at last visit, per 1 month increase 0.96 (0.90–1.02) 0.19 0.94 (0.89–1.00) 0.065
ART in use at last visit
Not on ART Ref. Ref.
On ART 0.40 (0.24–0.68) 0.001 0.68 (0.40–1.14) 0.144
Site
AMPATH-Kenya Ref. Ref.
ISS-Mbarara 8.5 (3.8–19.1) <0.001 9.7 (4.2–22.2) <0.001
Lighthouse-Malawi 10.5 (4.5–24.5) <0.001 12.1 (4.9–29.9) <0.001
UATH & NHA-Nigeria 6.6 (2.3–19.3) <0.001 8.7 (2.8–26.6) <0.001
ART denotes antiretroviral therapy; AMPATH denotes Academic Model Providing Access to Healthcare in western Kenya; ISS denotes Immune Suppression
Syndrome Clinic in Mbarara, Uganda; UATH denotes University of Abuja Teaching Hospital in Abuja, Nigeria; and NHA denotes National Hospital Abuja in
Abuja, Nigeria
a Adjusted risk ratios were derived using a generalized linear model with a binomial outcome and log link function. All variables are adjusted for all variables in
the column
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et al., studying 262 women with breast cancer diag-
nosed in a tertiary hospital in Uganda, reported that
35% become LTFU [21]. The investigators attempted
telephone tracking but again did not describe the out-
comes of this effort. Our study builds upon this prior
work by searching for what we believe is the largest
group of lost patients with a particular cancer in sub-
Saharan Africa, deriving these patients from a
community-level primary care-based sample, and
explicitly delineating the contribution of each of the
different elements of the tracking process.
Each component of the search process — manual review
of records, telephone calls and physical tracking in the
community — did indeed contribute. Because the initial
identification of lost patients used electronic records, we
hypothesized that clerical errors in recording completed
visits in the electronic databases might result in classifying
a truly non-lost patient as lost. Furthermore, because some
time did pass between the initial identification of appar-
ently lost patients and the time we began to search for
them, we recognized that some patients who had been
deemed lost at the time of electronic database closure
might have subsequently returned to care. Indeed, both of
the scenarios occurred, and the manual record review up-
dated an important fraction of nominally lost patients.
Telephone calls resulted in updating vital status in about
one-quarter of those truly LTFU. Nigeria had the most suc-
cess with telephone tracking, which is not surprising be-
cause the country has one of the highest concentrations of
cellphone users in Africa [30]. The third method, physical
tracking, found the largest fraction of lost patients. Al-
though we did not set out to evaluate this in the present
study, we believe that the mindset we bestowed upon our
trackers during our training was critical in their success.
That is, we instilled a mentality of looking harder and
spending more time on fewer patients — with the goal of
determining vital status in each sought patient — than had
previously been performed for tracking done during rou-
tine clinical care at the respective sites. Most tracking that
occurs during routine clinical care is performed in order to
bring the lost patient back to care — an individual patient-
level perspective. In contrast, we emphasized a group-level
perspective: updating vital status in only a small fraction of
sought after patients yields little scientifically useful infor-
mation because we would have no way of being sure
whether our found population is representative of all lost
patients. Only by updating vital status in a high percentage
of the lost can we be certain that we have a representative
population. In addition to this training, the attributes that
we believe are crucial to trackers’ success include
0
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Fig. 2 The predicted risk of not being found after phone and physical tracking attempts among patients with Kaposi sarcoma who were lost to follow-up
at primary care sites in four countries in sub-Saharan Africa. The prediction is limited to patients who gave consent for tracking and who had sufficient in-
formation to attempt physical tracking. Predictions for each site and duration since becoming lost were derived from a generalized linear model
and have been adjusted for age, sex, duration since KS diagnosis at last visit, and antiretroviral therapy use. Each prediction represents the mean
value of predictions across all patients in the dataset (“marginal” prediction) at their observed values of age, sex, duration since KS diagnosis at last visit, and
antiretroviral therapy use. Calculations were performed using the margins command in Stata. AMPATH denotes Academic Model Providing Access to
Healthcare in western Kenya; ISS denotes Immune Suppression Syndrome Clinic in Mbarara, Uganda; UATH denotes University of Abuja Teaching Hospital
in Abuja, Nigeria; NHA denotes National Hospital Abuja in Abuja, Nigeria
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perseverance and intimate knowledge of the local language,
culture, and geography.
We found no evidence that duration of being lost
was associated with our ability to update vital status.
We believe this reflects stable social settings in these
regions and the oft-availability of either the patient or
his/her informants at the original telephone number
or residence. Our finding suggests that searching for
lost patients can be performed every 3 to 5 years if
resources do not permit more frequently. In contrast,
while the overall success of tracking (among those
with a potential of being found) was acceptable at
each site (≥68%), it was most successful in Kenya.
Because site encompasses a number of different
constructs, including accuracy of contact information
in the records, ease of travel for the trackers, expert-
ise of the trackers, and willingness of the community
to provide information to the trackers, we cannot
determine which explains the geographic differences.
One exception is in Malawi where a substantial
percentage of lost patients had already undergone one
round of tracking during that clinic’s routine clinical
operations such that patients who remained lost at
the time we searched for them represented those who
were most difficult to update.
The main limitation of our work is that we assessed the
feasibility of searching for lost patients in settings which
had not been fully prepared for this endeavor. Specifically,
information on telephone numbers and residence, as well
as consent to search, was obtained during the course of
routine care without knowledge that an intense search
would later occur for purposes of group-level survival esti-
mation if a patient became lost. Hence, in some instances
of lost patients, there was no consent or serviceable loca-
tor information, which precluded our ability to search.
Therefore, we could not determine how successful the
search for the lost can be under optimal conditions in
which clinics pay close attention to comprehensive con-
senting and recording of locator information. We did at-
tempt to estimate success at tracking under optimal
conditions by limiting an analysis to lost patients who had
given consent to be tracked and had sufficient locator in-
formation available. In this group, we were able to update
vital status in a very high proportion (88%).
Conclusions
Our findings have implications for both clinical care
venues and cancer epidemiology. Any clinic which
routinely records telephone contacts and geographic resi-
dence on its patients can follow our described approach
and begin searching for its lost patients; outcomes will be
dependent upon the completeness and detail of the loca-
tor data. Thus, clinics who wish to be highly successful in
this regard should begin to comprehensively record and
update locator information using standardized protocols
and consent all patients to be searched for if they become
lost. Such recording can be done inexpensively. In
addition to searching for lost patients to update vital sta-
tus, clinics can also benefit from asking patients who vol-
itionally drop out of care (or their close informants) the
reasons why they left. For cancer epidemiology, the ability
to update vital status, especially in a primary case-based
sample of cancer cases, paves the way towards accurate
estimation of cancer survival. While our data was gener-
ated for patients with HIV-related KS, we strongly believe
our inferences extend to other cancers. We therefore urge
cancer epidemiologists to collaborate with sentinel pri-
mary care clinics in their regions to identify cohorts of
cancer patients, search for the lost patients amongst them,
and ultimately make accurate estimates of cancer survival.
We believe that such collaborations are much more
achievable and will yield actionable estimates of
cancer survival than are attempts to emulate the
more pristine population-based cancer registries of
resource-rich areas.
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